| Autor: |
Cârstea, Andrei Puiu, Mită, Adrian, Fortofoiu, Mircea-Cătălin, Doica, Irina Paula, Cârstea, Doina, Beznă, Cristina Maria, Negroiu, Cristina Elena, Diaconu, Ileana-Diana, Georgescu, Andreea-Roberta, Kamal, Adina Maria, Mahler, Beatrice, Grigorie, Adriana-Gabriela, Dobrinescu, Gabriel Adrian |
| Předmět: |
|
| Zdroj: |
Healthcare (2227-9032); May2023, Vol. 11 Issue 10, p1399, 12p |
| Abstrakt: |
Background: During the SARS-CoV-2 pandemic period, in the treatment approved by the WHO, along with antivirals, antibiotics, nonsteroidal anti-inflammatory drugs and anticoagulants, dexamethasone was always used. This study started from the professional concern related to the vasopressor effect of cortisone on blood pressure (BP). Methods: The study group was achieved by selecting, from a total of 356 patients hospitalized in the clinic, the patients with known hypertensive status at admission for SARS-CoV-2. Dexamethasone was part of the anti-COVID-19 treatment, with an administration of 4–6–8 mg/day, depending on bodyweight, for 10 days. All patients with hypertension received antihypertensive treatment in adjusted doses according to the recorded BP values. Results: Monitoring of BP in hospitalized patients was performed daily, in the morning and evening. If on the 2nd day of treatment, 84% of the patients partially responded to the treatment with a moderate decrease in BP, on the 3rd therapy day, the situation clearly improved: more than 75% of the patients had values of BP that can be classified as high-normal (38.23%) and normal (40.03%). Conclusions: Dexamethasone for treatment of SARS-CoV-2 infection did not have a notable influence on increasing BP, because the doses were low–moderate and prescribed for a short time. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
